CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
November 06 2007 - 11:00AM
PR Newswire (US)
- Data confirms safety and HbA1c reductions seen in ischemic
patients with diabetes in earlier clinical trials - ORLANDO, Fla.,
Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
(NASDAQ:CVTX) announced today that data from a prospectively
identified analysis of 2,220 diabetic patients from the MERLIN
TIMI-36 study showed that Ranexa(R) (ranolazine extended-release
tablets) significantly reduced hemoglobin A1c (HbA1c), increased
the number of patients achieving the clinical HbA1c treatment
target of 7.0 percent or less and reduced the incidence of newly
increased HbA1c in patients without diabetes at baseline. The
findings were presented today at the American Heart Association
Scientific Sessions in Orlando, Florida by Dr. David Morrow of the
TIMI Study Group. In patients with diabetes treated with Ranexa in
the study, at four months HbA1c had declined approximately 0.7
percentage points, from a starting mean baseline of 7.5 to 6.8
percent, and 0.43 percentage points compared to placebo (p
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024